ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Five Institutions To Test Interferon; Appendectomy-Cancer Association Noted

October 27, 1978

Cancer society, In Major Restructure, Forms New Executive Committee, Bylaws

November 20, 1992

Part One Of A Two-Part Interview With NCI Director Harold Varmus

July 22, 2011

New AIDs System For Classification Increase By 1% Cases Reported

August 1, 1986

White House Yet To Name NCAB, Cancer Panel Members

February 11, 2011

NCI Breast Tissue Registry Available To Researchers

March 24, 1995